Switch theme
Sign up to access all valuation multiples
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
1931
77.3K+
LTM Revenue $41.8B
LTM EBITDA $20.5B
$401B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Novo Nordisk has a last 12-month revenue of $41.8B and a last 12-month EBITDA of $20.5B.
In the most recent fiscal year, Novo Nordisk achieved revenue of $40.6B and an EBITDA of $19.2B.
Novo Nordisk expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Novo Nordisk valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $24.7B | $32.4B | $40.6B | $41.8B | XXX |
| Gross Profit | $20.7B | $27.4B | $34.3B | XXX | XXX |
| Gross Margin | 84% | 85% | 85% | XXX | XXX |
| EBITDA | $10.6B | $16.0B | $19.2B | $20.5B | XXX |
| EBITDA Margin | 43% | 49% | 47% | 49% | XXX |
| Net Profit | $7.8B | $11.7B | $14.1B | XXX | XXX |
| Net Margin | 31% | 36% | 35% | XXX | XXX |
| Net Debt | $1.2B | $962M | $11.2B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Novo Nordisk's stock price is DKK 630 (or $88).
Novo Nordisk has current market cap of DKK 2.80T (or $391B), and EV of DKK 2.87T (or $401B).
See Novo Nordisk trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $401B | $391B | XXX | XXX | XXX | XXX | $3.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Novo Nordisk has market cap of $391B and EV of $401B.
Novo Nordisk's trades at 9.6x LTM EV/Revenue multiple, and 19.6x LTM EBITDA.
Analysts estimate Novo Nordisk's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Novo Nordisk and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $401B | XXX | XXX | XXX |
| EV/Revenue | 9.9x | XXX | XXX | XXX |
| EV/EBITDA | 20.9x | XXX | XXX | XXX |
| P/E | 27.7x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 41.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNovo Nordisk's NTM/LTM revenue growth is 21%
Novo Nordisk's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Novo Nordisk's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Novo Nordisk's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Novo Nordisk and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 47% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 68% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 40% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novo Nordisk acquired XXX companies to date.
Last acquisition by Novo Nordisk was XXXXXXXX, XXXXX XXXXX XXXXXX . Novo Nordisk acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Novo Nordisk founded? | Novo Nordisk was founded in 1931. |
| Where is Novo Nordisk headquartered? | Novo Nordisk is headquartered in Denmark. |
| How many employees does Novo Nordisk have? | As of today, Novo Nordisk has 77.3K+ employees. |
| Who is the CEO of Novo Nordisk? | Novo Nordisk's CEO is Mr. Lars Fruergaard Jorgensen. |
| Is Novo Nordisk publicy listed? | Yes, Novo Nordisk is a public company listed on CSE. |
| What is the stock symbol of Novo Nordisk? | Novo Nordisk trades under NOVO B ticker. |
| When did Novo Nordisk go public? | Novo Nordisk went public in 1993. |
| Who are competitors of Novo Nordisk? | Similar companies to Novo Nordisk include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Novo Nordisk? | Novo Nordisk's current market cap is $391B |
| What is the current revenue of Novo Nordisk? | Novo Nordisk's last 12-month revenue is $41.8B. |
| What is the current EBITDA of Novo Nordisk? | Novo Nordisk's last 12-month EBITDA is $20.5B. |
| What is the current EV/Revenue multiple of Novo Nordisk? | Current revenue multiple of Novo Nordisk is 9.6x. |
| What is the current EV/EBITDA multiple of Novo Nordisk? | Current EBITDA multiple of Novo Nordisk is 19.6x. |
| What is the current revenue growth of Novo Nordisk? | Novo Nordisk revenue growth between 2023 and 2024 was 25%. |
| Is Novo Nordisk profitable? | Yes, Novo Nordisk is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
